secwatch / observer
8-K filed November 7, 2023, 6:59 PM ET ticker ABUS CIK 0001447028
leadership confidence high sentiment neutral materiality 0.65

Arbutus Biopharma CEO William Collier to retire Dec 31; COO McElhaugh named interim CEO

Arbutus Biopharma Corp

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William H. Collier

President and Chief Executive Officer
ABUS · Arbutus Biopharma Corp
Effective
2023-12-31
Successor
Michael J. McElhaugh
Filed
November 7, 2023, 6:59 PM ET
On November 1, 2023, William H. Collier informed Arbutus Biopharma Corporation (the “Company”) of his retirement as the Company’s Chief Executive Officer (“CEO”) and from the Board of Directors (the “Board”) of the Company, effective as of December 31, 2023.
Appointed (interim)

Michael J. McElhaugh

Interim President and Chief Executive Officer
ABUS · Arbutus Biopharma Corp
Effective
2024-01-01
Filed
November 7, 2023, 6:59 PM ET
the Board appointed Michael J. McElhaugh, Co-founder and Chief Operating Officer of the Company, as interim President and CEO, effective January 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William H. Collier retired as President and Chief Executive Officer at Arbutus Biopharma Corp.

Action
retired
Role
President and Chief Executive Officer
Exact text from the filing
On November 1, 2023, William H. Collier informed Arbutus Biopharma Corporation (the “Company”) of his retirement as the Company’s Chief Executive Officer (“CEO”) and from the Board of Directors (the “Board”) of the Company, effective as of December 31, 2023.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Michael J. McElhaugh was appointed as Interim President and Chief Executive Officer at Arbutus Biopharma Corp.

Action
appointed
Role
Interim President and Chief Executive Officer
Exact text from the filing
the Board appointed Michael J. McElhaugh, Co-founder and Chief Operating Officer of the Company, as interim President and CEO, effective January 1, 2024.
View on SEC.gov

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR
accession 0001171843-23-006795
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.